US Patent

US11406638 — Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2038-10-22 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a combination treatment for progressive fibrosing interstitial lung diseases (PF-ILD) that includes Nintedanib and a PDE4B-inhibitor.

USPTO Abstract

The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula Iwherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms andwherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A,wherein S* is a sulphur atom that represents a chiral centeror a pharmaceutically acceptable salt thereof.Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula IIIor a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4373 — Jascayd
U-4373 — Jascayd

Patent Metadata

Patent number
US11406638
Jurisdiction
US
Classification
Method of Use
Expires
2038-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.